US 12,030,947 B2
Humanized and affinity matured antibodies to FcRH5 and methods of use
Isidro Hotzel, Brisbane, CA (US); Teemu T. Junttila, San Mateo, CA (US); Ji Li, South San Francisco, CA (US); Justin Scheer, South San Francisco, CA (US); Danielle Dicara, South San Francisco, CA (US); Diego Ellerman, San Francisco, CA (US); Christoph Spiess, Mountain View, CA (US); and Paul J. Carter, Hillsborough, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Oct. 29, 2021, as Appl. No. 17/514,824.
Application 17/514,824 is a division of application No. 16/395,009, filed on Apr. 25, 2019, granted, now 11,192,950.
Application 16/395,009 is a division of application No. 15/184,690, filed on Jun. 16, 2016, granted, now 10,323,094, issued on Jun. 18, 2019.
Claims priority of provisional application 62/180,459, filed on Jun. 16, 2015.
Prior Publication US 2022/0048993 A1, Feb. 17, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 39/40 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01)
CPC C07K 16/283 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/62 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/70535 (2013.01)] 70 Claims
 
1. A method of treating or delaying the progression of an FcRH5-positive cancer in a subject in need thereof, the method comprising administering to the subject a bispecific antibody comprising a first binding domain that binds Fc Receptor-like 5 (FcRH5) and a second binding domain that binds cluster of differentiation 3 (CD3), wherein the first binding domain comprises the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23.